Multiple Ascending Dose (MAD) Phase Ib/II Study of the mTOR Inhibitor (RAD001) in Combination With the IGF-1R Antagonist (R1507) for the Treatment of Patients With Advanced Solid Tumors

Inclusion Criteria:

- adult patients, >=18 years of age;

- histologically confirmed recurrent or refractory advanced solid tumor (Part 1);

- advanced metastatic renal cell cancer OR advanced metastatic pancreatic
neuroendocrine tumors, with evidence of progressive disease (Part 2);

- measurable disease (Part 2);

- ECOG performance status 0-2.

Exclusion Criteria:

- prior treatment with agents acting via inhibition of IGF-IR pathway;

- prior treatment with agents acting via inhibition of mTOR (Part 2);

- untreated CNS metastases;

- current anti-cancer therapy, or radiotherapy or chemotherapy <=4 weeks prior to
enrollment;

- other known malignancy requiring treatment.